Search - tctmd.com

Displaying 1 - 20 of 852

Sort: Relevancy | Date

News Conference News ACC 2026

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

Michael O'Riordan

April 01, 2026

News Conference News ACC 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

Michael O'Riordan

March 30, 2026

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

News Daily News

Genomics, Lipids, Inflammation at Midlife Predict Future CAD

Caitlin E. Cox

March 25, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Daily News

Oral Anticoagulation Alone Best for Stable CAD Patients With AF: Meta-analysis

Yael L. Maxwell

March 12, 2026

News Conference News CRT 2026

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients

L.A. McKeown

March 09, 2026

News Conference News CRT 2026

CRT 2026: What to Expect in Washington, DC

L.A. McKeown

March 04, 2026

News Daily News

Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone

Michael O'Riordan

March 03, 2026

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

Todd Neale

January 05, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Risk Calculators Miss Many Patients Who Present With First MI

Michael O'Riordan

November 21, 2025

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Daily News

Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients

Caitlin E. Cox

October 16, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Daily News

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

L.A. McKeown

October 09, 2025

Advertisement

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Genomics, Lipids, Inflammation at Midlife Predict Future CAD

What’s Going to Be Hot at ACC 2026

Oral Anticoagulation Alone Best for Stable CAD Patients With AF: Meta-analysis

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients

CRT 2026: What to Expect in Washington, DC

Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone

Side Effects of Statins Might Be Overstated: CTT Collaboration

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

Year in Review: Top Prevention Stories of 2025

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Risk Calculators Miss Many Patients Who Present With First MI

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients

What’s Going to Be Hot at TCT 2025

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content